Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 721–744 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Benign Prostate Tissue
Interventions: Not listed
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Gut Microbiota, Psychological Distress
Interventions: freeze-dried table grape powder, Placebo; Dietary Supplement
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 30 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 62
States / cities: Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 54 more

Conditions: Fungal Infection
Interventions: Placebo, Rezafungin; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Perioperative Inflammatory Response
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sleep, Anxiety, Depression, Pain
Interventions: fsCBD Cannabidiol, Placebo, bsCBD Cannabidiol; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 25 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: adjunctive treatment with buspirone, placebo; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Respiratory Syncytial Virus (RSV)
Interventions: RSV-F Vaccine, Phosphate Buffer Placebo; Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 1,330 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 10
States / cities: Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more

Conditions: Asthma
Interventions: Montelukast 10 mg orally, Placebo; Drug · Other
Lead sponsor: Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.; Other
Eligibility: 65 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Alzheimers Disease
Interventions: Gantenerumab, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 32
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 28 more

Conditions: Type1 Diabetes
Interventions: HCL, verapamil 120mg tablet, non-HCL, placebo; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Conditions: Actinic Keratosis, Photodynamic Therapy
Interventions: Celecoxib 200mg, Placebo; Drug
Lead sponsor: Wright State University; Other
Eligibility: 45 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Fairborn, Ohio

Conditions: Cocaine Dependence, Cocaine Abuse, Cocaine Addiction, Substance Abuse
Interventions: Placebo, Cabergoline; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Interventions: CD-NP; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: ponsegromab, placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 982 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 91
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 48 more

Conditions: Type II Diabetes Mellitus
Interventions: JTT-130, JTT-130 Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 48
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Scottsboro, Alabama + 45 more

Conditions: Atopic Dermatitis
Interventions: ASN002, Placebo Oral Tablet; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 30
States / cities: Anniston, Alabama • Birmingham, Alabama • Fremont, California + 24 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: NS2359, Placebo; Drug
Lead sponsor: NeuroSearch A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer - Female
Interventions: Melatonin, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Acute Kidney Injury
Interventions: Basis, Placebo; Dietary Supplement
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Insomnia, Asthma
Interventions: Ramelteon; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetic Peripheral Neuropathy
Interventions: Bicifadine; Drug
Lead sponsor: XTL Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 336 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: Hypoglycemia, Diabetes Mellitus, Type 1
Interventions: Dasiglucagon, Placebo; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 3
States / cities: Chula Vista, California • Escondido, California • Renton, Washington

Conditions: Hidradenitis Suppurativa
Interventions: Placebo, LY3041658; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 15
States / cities: Rogers, Arkansas • Fountain Valley, California • Los Angeles, California + 12 more

Search by objective public record fields.

Long-term Effects of Dutasteride on Architectural and Nuclear Morphometric Features of Benign Prostate Tissue

Effects of Grape Powder on Psychological Distress and Gut Microbiota in College Students

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Safety and Pharmacokinetics of Rezafungin

Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery

Cannabis for Palliative Care in Cancer

Serotonin 1A Agonists and Cognition in Schizophrenia

Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.

Asthma in the Elderly: The Effect of Montelukast

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes

Photodynamic Therapy-Induced Immune Modulation: Part III

A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence

CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Efficacy and Safety of NS2359 in Adults With Attention Deficit Hyperactivity Disorder

Melatonin Supplementation for Cancer-related Fatigue in Patients Receiving Radiotherapy

Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

Ramelteon for Insomnia Comorbid With Asthma

Double Blind RCT of Bicifadine SR in Outpatients With Chronic Neuropathic Pain Associated With Diabetes

Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM

A Study of LY3041658 in Adults With Hidradenitis Suppurativa